Tag Archives: MTC

PR Newswire

Pangyo Techno Valley’s 100 Bio & Medical Special – MIK HOT SPOT Online Exhibition to open on September 4

Leave a comment

New attempt to promote Korean companies to domestic and foreign markets in post-coronavirus era.

SEOUL, South Korea, Sept. 25, 2020 — AVING NEWS’ Korea’s only convention media and online exhibition center by itself, began this project to help Korean companies to enter the domestic and foreign markets through MIK HOT SPOT (Made in Korea Online Exhibition) on its way to become the global online hot spot.

The online exhibition consists of opening the MIK ONLINE HOT SPOT exhibition, business introduction video for buyers and investors, domestic and global promotion, target promotion for MIK HOT SPOT network, and post-management after contacting the buyers and investors, open for 365 days a year.

The five companies that participated in the MIK HOT SPOT_Pangyo Techno Valley 100 Bio & Medical Special are as follows:

  • M2S
  • Rootee Health
  • Exosystems
  • Genome & Company
  • AllLive Healthcare

– M2S

M2S, a digital healthcare specialist, is a startup company that develops and operates eye-related care services and platforms, including its VR ophthalmic testing device VROR. M2S has received spotlight in the global market when VROR, the ophthalmic testing device using virtual reality (VR), was approved by the US FDA in December of last year. The company has 12 domestic and foreign patents related to ophthalmic examination, including the domestic original patents for ophthalmic examination with VR and eye tracking technology. To enter the global market with the ability to create innovative VR AR-based digital contents, M2S is planning to launch Eye.Dr VR, a digital healthcare solution for eye health management in September.

– Rootee Health

ELI Solution provided by Rootee Health is an eye disease test solution that can be easily used by the general public. The feature of this product lies in the eye examination automation technology that automates the process of obtaining good images with AI technology while being portable. "If you just place your face like a VR, the eye exam is done within 10 seconds, and you can finish the eye exam for both eyes within 30 seconds. It is the first portable automatic photographic eye exam device. Because it is portable, it has a big advantage over conventional fixed fundus camera," CEO Guk Gyeong-min said.

– Exo Systems

Lee Hu-man, the CEO of Exosystems, has developed ExoRehab that helps rehabilitate the musculoskeletal system as he founded the company. CEO Lee said, "The most core value of ExoRehab is to train and restore the muscles that make up the musculoskeletal system. The biosignal wearable device analyzes the biosignals of the wearer and provides an exercise program suitable for them in software form. For those who have difficulty in exercising, it provides medical electrical stimulation to help restore muscle."

– Genome & Company

Genome & Company is a bio-venture company established in 2015, developing next-generation innovative new drugs in the field of immune anticancer drugs such as microbiome, new target immune checkpoint inhibitors, and fusion proteins to overcome unmet medical demands of cancer patients. The company is the first Korean microbiome research and development company to collaborate in a clinical trial of concomitant use and supply contract of Merck and Pfizer’s immune anticancer drug Avelumab (product name: Bavencio) and its own immune anticancer microbiome treatment (GEN-001) in December last year. In April of this year, the US Food and Drug Administration (FDA) approved the clinical trial plan (IND), and the clinical trial of concomitant use is in progress. Along with this. in December last year, it concluded an MOU with LG Chem for the exclusive development and commercialization rights for GEN-001 in Korea and the East Asian region.

– AllLive Healthcare

AllLiveC is a platform operated by AllLive Healthcare, Korea’s no. 1 clinical trial support service provider. It is providing the clinical trial online/offline integrated brokerage service that connects applicants who want to participate and the clinical trial centers. Clinical trial is the most important process in the development of new drugs, and a huge amount of time and money is spent. AllLive Healthcare has the goal to innovate these clinical trials with IT technology, and as the first step, it has made the platform that provides the service of recruiting and managing the subjects for clinical trials. By using the IT technology, the recruitment of clinical trial subjects that had been conducted manually is done by AllLiveC, the clinical online/offline clinical trial brokerage service’ It is announcing the clinical trials by online media.

Pangyo Techno Valley, which participated in MIK HOT SPOT (Made in Korea Online Exhibition), is a business platform where companies with innovative products and technologies are gathered. About 1,300 companies in IT, CT, and BT sectors are based here. Innovative companies with global capabilities like Kakao, NHN Entertainment, AhnLab, Krafton, NCSOFT, Nexon, and Hancom, and advanced technology research institutes like Advanced Institute of Convergence Technology, KAIST, ETRI, and KETI are working together.

The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea’s largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year.

The MIK HOT SPOT online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.

– Go to MIK Hot Spot (Made in Korea Online Exhibition) special page
http://www.madeinkorea.tv/

PR Newswire

Pharmalutions And Movilitas.Cloud Deliver Serialization Solutions for the Asia-Pacific Region

Leave a comment

Partnership Provides Greater Access to End-To-End Serialization and Track & Trace Solutions

COLUMBIA, Md., Sept. 11, 2020 — Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while improving operational efficiencies to deliver safer pharmaceuticals to patients.

Several countries in the Asia-Pacific region, such as Indonesia, Thailand and Malaysia, have already established or announced the introduction of serialization regulations for medicines. As track & trace regulations further spread and evolve, this partnership ensures that safer products reach consumers. It makes compliance for life science manufacturers simple, offering a holistic solution connecting the serialization equipment on the shop floor with an out-of-box level 3-5 track & trace solution that is configurable for the specific needs of different participants in the supply chain.

"We have been involved in product-serialization and aggregation since 2004," said Tilman Joerss, Founder and Director of Pharmalutions. "This is 15 years ahead of the EU-FMD deadline [February 2019], and it provided us with a valuable long-term perspective of the regulatory landscape and its evolutionary nature. Today, this broad experience serves our customers well in dealing with much faster approaching deadlines while safeguarding their long-run investments into product-traceability. Rapid deployment of future-proof technology. That is the key and why Movilitas.Cloud is a perfect match."

To learn more about the Movilitas.Cloud solution, please visit: https://www.movilitas.com/solutions/movilitas-cloud/

About Pharmalutions Pte LTD

Founded in 2010 in Singapore, Pharmalutions Pte Ltd is a specialist for multi-regulatory Track & Trace (T&T) based on product-serialization, with a distinct focus on pharmaceutical compliance. Pharmalutions evolved from Regional System Integrator to become a private-label in 2019. Today, Pharmalutions is an officially recognised GS1 Singapore Solution-Partner (SSP). A 10-years-history powers Pharmalutions with a unique long-term perspective on global T&T. Its deeply rooted network stretches from Europe to Asia-Pacific, across industries.

For more information, visit Pharmalutions.net or LinkedIn

About Movilitas

Movilitas is a technology leader delivering the next generation of solutions and consulting services across multiple industries to advance smart supply chain ecosystems. We are recognized as a trusted SAP partner for digital supply chain transformation. We help businesses realize new growth opportunities, adapt to today’s on-demand economy and maintain compliance. Through services, such as Movilitas.Cloud, or extensions and accelerators for SAP solutions, our clients unlock data to realize greater efficiencies and new revenue streams. For more information, visit movilitas.com, or LinkedIn, Twitter or Xing.

CONTACT: marketing@movilitas.com

Logo – https://techent.tv/wp-content/uploads/2020/09/pharmalutions-and-movilitas-cloud-deliver-serialization-solutions-for-the-asia-pacific-region.jpg

Related Links :

http://www.movilitas.com

PR Newswire

Infosys to Acquire Product Design and Development firm, Kaleidoscope Innovation

Leave a comment

Expands engineering services portfolio by strengthening presence in Medical devices, Consumer and Industrial markets across US

BENGALURU, India and CINCINNATI, Sept. 4, 2020 — Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire Kaleidoscope Innovation, a full-spectrum product design, development and insights firm innovating across medical, consumer and industrial markets, bolstering capabilities in the design of smart products. This acquisition demonstrates Infosys’ commitment to innovate for its clients, and make a meaningful impact on human lives by combining cutting-edge technologies and experiences to revolutionize patient care, treatment, diagnostics and consumer health across the world.

Kaleidoscope Innovation brings to Infosys a diverse talent pool with extensive knowledge of design and engineering. The company leverages a deep understanding of clinical environments, strong product development capabilities across domains, and a consultancy-style approach addressing human factors, product design, UI/UX design, research & insight, development and visualization. It serves a marquee and diversified customer base with state of the art, in-house labs, 3D design environments and customer experience centers. Kaleidoscope designs microsurgical instruments, devices used in minimally invasive surgery, drug delivery devices for ophthalmic therapies and user-centric wearables. It also offers usability testing in support of regulatory submissions, including the delivery mechanism for aortic stents.

Ravi Kumar, President, Infosys, said, "This acquisition further strengthens our digital offerings at the intersection of new software technologies and medical devices – a sector that is expected to witness significant investments and consumerization in the post-COVID era. Our clients will benefit from the combination of Kaleidoscope’s strong upstream offerings of product innovation and design, and Infosys’ stack of product engineering, validation and commercialisation services at a global scale. We are excited to welcome Kaleidoscope Innovation and its leadership team into the Infosys family, as part of Infosys Engineering Services portfolio."

Nitesh Bansal, SVP & Global Head of Engineering, Infosys, said, "Device engineering for both the consumer and medical industries has been a critical success parameter for our clients. The addition of upstream concept design and human factors engineering, through this acquisition not only provides us end-to-end capability, but also creates an engagement engine dedicated towards innovation and growth in this sector."

Matt Kornau, CEO & Co-Founder, Kaleidoscope Innovation said, "We are enthusiastic about our exciting new partnership with Infosys. It allows us to scale quickly and bring expanded offerings in AI, Analytics, and Digital Infrastructure to our clients. Kaleidoscope has always valued the ability to enhance people’s lives and their outcomes through innovation. We feel Infosys shares these same values and will open new avenues for our client partners, and our staff, to pursue larger opportunities together.  We will remain dedicated to serving as good partners to other companies, large and small, as we continue to meet our mission."

Bill Taylor, Co-Founder, Kaleidoscope Innovation added, "Infosys provides an exciting platform for us to extend our relationship with our Business Partners to address the productization of solutions they have been asking us to deliver. Having the technical prowess and bandwidth to offer solutions that address manufacturability and lifecycle management will benefit all parties. We can now offer them the scale needed for both front end innovation and back end implementation and sustainability"

The acquisition is expected to close during the second quarter of fiscal 2021, subject to customary closing conditions.

About Kaleidoscope Innovation

Kaleidoscope Innovation is a full-service product development firm innovating across medical, consumer and industrial markets. For over 30 years, clients have partnered with Kaleidoscope to improve the human experience. Kaleidoscope offers both consultancy-style and onsite services, across a full breadth of disciplines to meet their client’s needs where needed, including insights & human factors, medical affairs, industrial design & user experience, engineering, visualization and software development. For more information about Kaleidoscope Innovation, please visit www.kascope.com

About Infosys

Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With nearly four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.

Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2020. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Logo: https://mma.prnasia.com/media2/633365/Infosys_Logo.jpg?p=medium600

PR Newswire

Jvion Lauded by Frost & Sullivan for Improving Patient Outcomes Using Its Clinical-AI CORE™ Intelligence Platform

Leave a comment

Jvion’s prescriptive analytics approach identifies undetected risk and modifiable risk trajectories followed by recommendations for remedial actions

SANTA CLARA, California, Sept. 1, 2020 — Based on its recent analysis of the North American prescriptive analytics market, Frost & Sullivan recognizes Jvion, Inc. with the 2020 North American Technology Innovation Leadership Award for its clinical-AI Care Optimization and Recommendation Enhancement (CORE™) technology. It is a scalable, secure intelligence repository that aggregates structured as well as unstructured data and augments that information with clinical, socioeconomic, and experiential data on 30 million individuals to draw meaningful correlations and inferences. To date, Jvion’s clinical AI has helped more than 300 hospitals, payers, and pharmacy managers achieve 30 percent reductions in preventable adverse incidents, which translate to annual savings of more than $6.3 million.

2020 North American Prescriptive Analytics Technology Innovation Leadership Award
2020 North American Prescriptive Analytics Technology Innovation Leadership Award

"The CORE™ identifies health and financial risk trajectories that can be modified, delivers prioritized insights to the care teams and coordinators engaging patients, and makes recommendations to improve outcomes. As a prescriptive analytics solution, it can proactively mitigate preventable harm that could otherwise lead to hospital readmissions, serious conditions, or accelerated health deterioration," said Cecilia Van Cauwenberghe, Industry Principal. "With this first-in-class AI platform, Jvion evolved from a provider of simple predictive analytics and machine learning solutions to a technology leader that can help identify potentially high-risk patients and suggest specific remedial action."

The solution leverages a combination of Eigen-based mathematics, datasets from over 30 million patients, and a software platform to promptly act upon 50+ preventable clinical events, covering behavioral health, hospital acquired conditions, chronic conditions, hospice/palliative care, and medication adherence. Additionally, it can identify avoidable cost events including uncompensated care and help customers work with their patient population to identify the right financial assistance. Importantly, the CORE™ does not require the creation of new models or perfect datasets. The underlying AI capability assesses 4,500 clinical and non-clinical risk factors for every patient and a quadrillion risk calculations through 170,000 self-learning Eigen Spheres clusters in real-time.

Frequently used enterprise data warehouse or data lake models demand considerable resources just to deliver a retrospective view of the patient’s health risk. Similarly, scoring methods such as LACE and BRADEN do not provide enough granularity or patient specificity to determine all the factors impacting the patient’s health. Jvion’s CORE™, on the other hand, boasts patient specificity, high effectiveness (seven times more effective than popular scoring methods), patient rendering (up to 365 days view into the future), successful use of even incomplete and unstructured datasets, and the fastest speed to value. Each of these benefits helps deliver effective, personalized patient care.

"As a result of its patient-centric approach to understanding vulnerability and risk, Jvion was able to pivot quickly during a pandemic to launch its COVID Response Suite, which delivers lists of individuals most vulnerable to severe illness. These insights enable proactive and targeted outreach to individuals that need to take more aggressive precautions," noted Cauwenberghe. "The relevance of its solutions, along with its patient-focused technology development efforts, has positioned Jvion for accelerated growth."

"Jvion is honored to be recognized for executing on its mission of preventing avoidable harm whether categorized as a health or financial event for our customers," said Jay Deady, CEO of Jvion. "Our team is constantly innovating to ensure our prescriptive AI approach is relevant to the changing dynamics of the healthcare industry."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies that deliver significant customer value.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Harley Gadomski
P: 12104778469
E: harley.gadomski@frost.com

About Jvion, Inc.

Jvion, a leader in clinical artificial intelligence, enables providers, payers and other healthcare entities to identify and prevent avoidable patient harm, utilization and costs. An industry first, the Jvion CORE™ goes beyond predictive analytics and machine learning to identify patients on a trajectory to becoming high-risk. Jvion then determines the interventions that will more effectively reduce risk and enable clinical and operational action. The CORE accelerates time to value by leveraging established patient-level intelligence to drive engagement across healthcare organizations, populations, and individuals. To date, the Jvion CORE has been deployed across hundreds of clients and resulted in millions saved. For more information, visit http://www.jvion.com.

Media Contact:

Anya Nelson
Scratch Marketing + Media for Jvion
anyan@scratchmm.com 
617.817.6559

 

Related Links :

Frost New Home page v2

PR Newswire

GEN inCode Announces Completion of £3M Institutional Foundation Fundraise

Leave a comment

OXFORD, England, Sept. 1, 2020 — GEN inCode UK Limited, the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the completion of a £3.0M institutional fundraise to internationally scale its products and technology.   

GEN inCode specializes in genetic risk assessment and the prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease, such as angina and myocardial infarction, often referred to as "heart attack". CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. By 2030, the total global cost of CVD is set to rise from approximately US $863 billion in 2010 to US $1,044 billion and is both a major health issue and global economic burden.

GEN inCode’s CE marked invitro-diagnostic products provide genetic information to enable patients, doctors and healthcare practitioners to assess and predict the onset of CVD. The Company’s products and ‘cloud-based’ reporting system help inform healthcare practitioners and patients of their CVD risk, enabling behavioural change alongside delivery of the most effective course of treatment. 

GEN inCode has amassed significant investment in over 15 years’ worth of research data and the development of products and algorithms to assess disease risk and prevent the onset of CVD. In September 2018, the Company acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of The Ferrer Group, a large pharmaceutical and healthcare multinational company with headquarters in Barcelona, Spain. GEN inCode has now received institutional funding from Maven Capital Partners and Downing to expand its operations in Europe, the UK and U.S.

GEN inCode’s vision is to educate patients about their cardiovascular risk and to improve public health by using the predictive capability of its products with targeted therapies to determine lifestyle choice and improve patient outcomes.

Matthew Walls, Chairman and CEO, said: "We are delighted to complete the institutional round of funding and welcome Maven and Downing, our new institutional investors. The funding will prepare the Company for accelerated growth and international scale and supports our regulatory and clinical pathway into the U.S. market. We look forward to advising the market on our progress and further milestones in due course."

Jordi Puig, Co-founder and Group COO, said: "This marks another milestone in the development of our Company and prepares us to rapidly scale our products and technology across our European business."

Enquiries:

GEN inCode UK Limited

Matthew Walls

Tel +44 (0)7887 501998  

www.genincode.com

About GEN inCode:

GEN inCode is a UK-based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide.

GEN inCode UK Limited operates business units in Europe and Latin America through GEN inCode S.L.U., and in the United States through GEN inCode U.S. Inc.

GEN inCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.

PR Newswire

G-ray Switzerland announces new CEO, closes successful funding round

Leave a comment

NEUCHÂTEL, Switzerland, Aug. 31, 2020 — G-ray Switzerland, the medical imaging and industrial diagnosis start-up founded in 2014, has announced the appointment of Luis Pallares as Chief Executive Officer, as the company embarks on an accelerated growth drive and completes a successful funding round.

Mr Pallares is focused on leading the transformation of G-ray’s business development efforts following the company’s development of a disruptive and patented state of the art technology to bring safer, cheaper and better vision into imaging for medical and industrial diagnosis.

Mr Pallares joins G-ray with a wealth of entrepreneurial and start-up experience, having founded Spain’s first streaming service, Addhoc Streaming, Spanish-speaking health related content site Vivir Mejor, and Spain’s leading digital strategy firm, Nennisiwok.

Most recently Mr Pallares’ deep experience in technology development, artificial intelligence and digital advertising led him found Plyzer Technologies, a global leader of price comparison technology matched with business analytics and intelligence based on artificial intelligence.

The appointment coincides with the news that G-ray has also raised a further CHF 2.6 millions, enabling it close out its successful Series A funding round at CHF 28 million.

Luis Pallares, Chief Executive Officer of G-ray, said: "G-ray has already proven to be a positive disruptive force within the technology industry and I relish the opportunity to help deliver tangible progress by bringing improvements in imaging into medical and industrial diagnosis."

Mr Yves Claude Aubert, Chairman of G-ray Switzerland, said: "Our technology has already started to disrupt the multi-billion particle detection imaging markets, based on our proprietary and transformative unique detector architecture. As artificial intelligence impacts the traditional X ray detector market, Luis is the perfect choice to lead G-ray forward into a new phase of growth and to capture these opportunities.

About G-ray Switzerland

Founded in 2014 in Neuchâtel, G-ray Switzerland SA has filed a number of revolutionary patents in the fields of radiographic imaging and new semiconductor assembly techniques. The rapidly expanding company has developed core skills in monolithic detectors with integrated high-resolution CMOS circuits. These innovations cover a wide range of sectors, including automotive, aerospace and medicine. www.g-ray.ch

 

 

Related Links :

http://www.g-ray.ch

PR Newswire

First Rapid Corona Antigen Test Approved for Clinical Study in Germany

Leave a comment

The health tech company Digital Diagnostics AG from Mainz, Germany, has received approval for clinical trials from a German ethics committee and the Federal Institute for Drugs and Medical Devices (BfArM). This is a crucial regulatory step in the ongoing approval process for the Digid Cantisense™ SARS-CoV-2 test in Germany. The aim of the clinical trials is to demonstrate the reliability of the new technology in comparison with conventional PCR tests. The new test is particularly suitable for access control at airports or at large-scale event

MAINZ, Germany, Aug. 26, 2020 — In June 2020, the health technology company Digital Diagnostics AG from Mainz, applied for approval of the Digid Cantisense™ SARS-CoV-2 test for Germany at the German Federal Institute for Drugs and Medical Devices (BfArM). BfArM has now permitted the conduct of clinical trials in accordance with Section 20 (1) of the German Medical Devices Act (MPG). Meanwhile, the ethics committee of the Rheinland-Pfalz Medical Association (Landesärztekammer) has also given a positive vote.

Completion of the clinical evaluation of the Digid biosensor and the accompanying reading device is expected in October 2020. If the results meet expectations, the rapid Cantisense™ test shall be approved in short succession. Digital Diagnostics AG will then be able to launch the tests on the market in millions. The company currently develops the necessary production capacities, ready for use in time right after the approval.

The leading center to carry out the clinical trials is PFÜTZNER Science & Health Institute in Mainz, which works closely with scientists and MDs from corona test centers and clinics throughout Germany. It is planned to perform the study locally as well as in known German corona hotspots.

In the study, patients are tested in parallel with a standard PCR method and with the Digid Cantisense™ SARS-CoV-2 test. Like with all common SARS-CoV-2 determinations, medical staff takes a throat swab from the patient. The sample is analyzed directly on site with the Digid rapid test system and afterwards compared with the result of a PCR test from a reference laboratory to demonstrate the accuracy of the Digid Cantisense™ SARS-CoV-2 test. The design of the study complies with FDA and EU Commission guidelines for in-vitro measurement procedures to detect SARS-CoV-2.

One key advantage of the Digid Cantisense™ SARS-CoV-2 test is that it directly detects the presence of the virus in the sample, while other available rapid tests mostly detect antibodies. Patients only develop these antibodies if they have had an infection for several days, a time during which they were contagious and might unknowingly have infected others. With the unique combination of immediate on-site detection of the virus in tested patients, the Digid Cantisense™ SARS-CoV-2 test is particularly useful to contain the spread of the pandemic and suitable for on-site access control and rapid testing, for example at airports, in hospitals or at large-scale events.

Press contact

Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu

Related Links

Medium

Website

Related Links :

digid GmbH
PR Newswire

Sai Life Sciences opens new, state-of-the-art Research & Technology Centre in Hyderabad

Leave a comment

– Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)

– Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility

HYDERABAD, India, Aug. 17, 2020 — Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research and Technology (R&T) Centre in Hyderabad, India. Sri K T Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.

Sai Life Sciences New Research & Technology Centre
Sai Life Sciences New Research & Technology Centre

Speaking on the occasion, Sri KT Rama Rao said, "I’m very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D centre. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new Research & Technology Centre but, also for their work towards the development and manufacturing of new life saving medicines."

Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility has several unique aspects such as intelligent & ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, "Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities." He further added, "We are an example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made."

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company’s capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.

Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

About Sai Life Sciences
Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

Photo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad-3.jpg  
Photo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad.jpg  
Logo: https://techent.tv/wp-content/uploads/2020/08/sai-life-sciences-opens-new-state-of-the-art-research-technology-centre-in-hyderabad-2.jpg

Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon'ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce
Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon’ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce

 

 

PR Newswire

111 to Announce Second Quarter 2020 Unaudited Financial Results on August 20, 2020

Leave a comment

SHANGHAI, July 31, 2020 — 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2020, before the U.S. market opens on Thursday, August 20, 2020.

111’s management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 20, 2020 (7:30 PM Beijing Time on the same day).

Details for the conference call are as follows:

Event Title:                       

111, Inc. Second Quarter 2020 Earnings Conference Call

Registration Link:            

http://apac.directeventreg.com/registration/event/7482148

All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.

Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.

A telephone replay of the call will be available after the conclusion of the conference call until August 28, 2020, 09:59 P.M. ET on:

United States:                    

+1-855-452-5696

International:                      

+61-2-8199-0299

Conference ID:                   

7482148

A live and archived webcast of the conference call will be available on the Investor Relations section of 111’s website at http://ir.111.com.cn/.

About 111, Inc.

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a Company dedicated to digitally connecting patients with drugs and healthcare services in China. The Company provides hundreds of millions of consumers with better access to pharmaceutical products and medical services directly through its online retail pharmacy and indirectly through its offline pharmacy network. 111 also offers online medical services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation and electronic prescription services. In addition to providing direct services to consumers through its online retail pharmacy, 111 also enables offline pharmacies to better serve their customers.  The Company’s online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. The Company’s New Retail platform, by integrating the front and back ends of the pharmaceutical supply chain, has formed a smart supply chain, which transforms the flow of pharmaceutical products to pharmacies and modernizes how they serve their customers.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:

111, Inc.
Investor Relations
Email: ir@111.com.cn

111, Inc.
Media Relations 
Email: press@111.com.cn 
Phone: +86-021-2053 6666 (China)

GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international

Related Links :

http://www.yiyaowang.com

PR Newswire

DriWay Technologies Commences Bomb Shelter Pilot Project with Korean Government

Leave a comment

The Daejeon City Government will use DriWay’s dehydration devices, starting in a key bomb shelter, to remove invasive moisture and improve air safety.

NEW YORK, July 29, 2020 — The Republic of Korea’s Daejeon City Government has commissioned DriWay Technologies to install its dehydration devices in the city’s bomb shelters, to reduce the invasive moisture within the structures. This partnership begins with a three-month pilot project in the Dunsan Fire Station bomb shelter, with installation to take place the first week of August 2020.

South Korea maintains approximately 19,000 bomb shelters throughout the country for civilian use in an emergency, such as potential missile attacks from North Korea. Many such shelters are located within structures like fire stations.

Daejeon, the country’s fifth largest metropolis, has declared its commitment to ensuring that the air quality in these bunkers is safe and healthy for its citizens. Upon encountering invasive building moisture that obstructed a summer 2020 renovation project in the Dunsan Fire Station, Daejeon city leaders initiated a partnership with DriWay to address the problem using DriWay’s dehydration devices.

DriWay’s patented technology naturally breaks the attraction that causes groundwater to rise into buildings, allowing a combination of evaporation and gravity to remove excess water from the walls. Without requiring any potentially hazardous chemicals or electrical power, it provides a sustainable, permanent, and environmentally friendly solution for building owners, managers, and occupants.

“The leadership of Daejeon, including Construction Department Chief Kim Jong Shin, have shown admirable dedication to the security and wellbeing of the people they serve. It is an honor for us to be entrusted with something as important as keeping the air within these bunkers safe and healthy for the city’s residents,” said Steve Kim, COO of DriWay Korea.

“We are proud to serve the city of Daejeon and help protect its residents by providing them with better air quality in its shelters,” said Roy Judelson, Global Chairman and CEO of DriWay Technologies. “These shelters are critical for keeping residents of South Korea safe from outside harm, and our priority is to support Daejeon’s leadership in also keeping residents safe from health hazards caused by invasive moisture inside the shelters.”

About DriWay Technologies
DriWay Technologies is a building health technology company that addresses the environmental and health hazards caused by invasive moisture: mold-causing ground moisture that naturally enters building foundations, basements, and ground floors and can inflict health risks, structural damage, and increased thermal insulation costs. This problem plagues 10% of buildings in the US, and higher percentages in other regions of the world, according to a 2019 EY market study.

DriWay is headquartered in London, with subsidiaries in the US, UK, UAE, and South Korea. It is currently providing its services to the US Government and marquee clients such as Grosvenor Group in London, Nakheel Properties in Dubai, Olshan Properties in New York City, and Hyundai Corporation in South Korea. In the next year, DriWay will also be expanding its operations into India, Japan, Indonesia, Greece, and Cyprus after recently completing a Seed Round financing at a $100 million valuation.

For all media inquiries, please contact media@driway.com.